BRANDYWINE MANAGERS, LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
7234 LANCASTER PIKE HOCKESSIN, DE 19707
As of the latest 13F report, the guru’s equity portfolio contained 37 stocks valued at a total of $29.00Mil. The top holdings were PATH(19.31%), CRWD(10.55%), and MRNA(5.97%).
According to GuruFocus data, these were BRANDYWINE MANAGERS, LLC’s top five trades of the quarter.
Prime Medicine Inc
The guru established a new position worth 32,977 shares in NAS:PRME, giving the stock a 2.14% weight in the equity portfolio. Shares traded for an average price of $18.06 during the quarter.
On 02/18/2023, Prime Medicine Inc traded for a price of $18.75 per share and a market cap of $1.82Bil. The stock has returned 0.00% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Prime Medicine Inc has a EV-to-Ebitda ratio of -23.40.
Mobileye Global Inc
The guru established a new position worth 13,067 shares in NAS:MBLY, giving the stock a 1.6% weight in the equity portfolio. Shares traded for an average price of $30.35 during the quarter.
On 02/18/2023, Mobileye Global Inc traded for a price of $43.95 per share and a market cap of $35.24Bil. The stock has returned 0.00% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Mobileye Global Inc has a price-book ratio of 2.38, a EV-to-Ebitda ratio of 131.10 and a price-sales ratio of 34.68.
Ionis Pharmaceuticals Inc
The guru sold out of their 8,460-share investment in NAS:IONS. Previously, the stock had a 1.23% weight in the equity portfolio. Shares traded for an average price of $42.06 during the quarter.
On 02/18/2023, Ionis Pharmaceuticals Inc traded for a price of $38.6 per share and a market cap of $5.48Bil. The stock has returned 17.90% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 4 out of 10.
In terms of valuation, Ionis Pharmaceuticals Inc has a price-book ratio of 9.21, a EV-to-Ebitda ratio of 135.27 and a price-sales ratio of 6.24.
The price-to-GF Value ratio is 1.29, earning the stock a GF Value rank of 1.
Varonis Systems Inc
The guru sold out of their 13,580-share investment in NAS:VRNS. Previously, the stock had a 1.18% weight in the equity portfolio. Shares traded for an average price of $22.85 during the quarter.
On 02/18/2023, Varonis Systems Inc traded for a price of $27.33 per share and a market cap of $2.94Bil. The stock has returned -31.52% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Varonis Systems Inc has a price-book ratio of 5.86, a EV-to-Ebitda ratio of -26.18 and a price-sales ratio of 6.35.
The price-to-GF Value ratio is 0.50, earning the stock a GF Value rank of 4.
Beam Therapeutics Inc
BRANDYWINE MANAGERS, LLC reduced their investment in NAS:BEAM by 5,000 shares. The trade had a 0.78% impact on the equity portfolio. During the quarter, the stock traded for an average price of $44.79.
On 02/18/2023, Beam Therapeutics Inc traded for a price of $43.17 per share and a market cap of $3.04Bil. The stock has returned -37.45% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Beam Therapeutics Inc has a price-book ratio of 4.26, a EV-to-Ebitda ratio of -6.72 and a price-sales ratio of 32.41.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
